• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

卡介苗膀胱内灌注治疗膀胱癌期间白细胞介素-2的产生

Interleukin-2 production during intravesical bacille Calmette-Guerin therapy for bladder cancer.

作者信息

Ratliff T L, Haaff E O, Catalona W J

出版信息

Clin Immunol Immunopathol. 1986 Aug;40(2):375-9. doi: 10.1016/0090-1229(86)90043-7.

DOI:10.1016/0090-1229(86)90043-7
PMID:3487405
Abstract

Interleukin-2 (IL-2) was detected in urine but not serum of patients receiving intravesical bacille Calmette-Guerin (BCG) therapy for bladder cancer. IL-2 activity was neutralized by anti-IL-2 antibody. No IL-2 was detected in urine before BCG therapy or from control donors. BCG-induced urine IL-2 peaked 4-8 hr after treatment but was rarely observed after 24 hr. The presence of BCG-induced lymphokines may be associated with antitumor activity.

摘要

在接受卡介苗（BCG）膀胱灌注治疗膀胱癌的患者尿液中检测到白细胞介素-2（IL-2），但血清中未检测到。IL-2活性可被抗IL-2抗体中和。在BCG治疗前的尿液或对照供体的尿液中未检测到IL-2。BCG诱导的尿液IL-2在治疗后4-8小时达到峰值，但24小时后很少观察到。BCG诱导的淋巴因子的存在可能与抗肿瘤活性有关。

相似文献

1
Interleukin-2 production during intravesical bacille Calmette-Guerin therapy for bladder cancer.卡介苗膀胱内灌注治疗膀胱癌期间白细胞介素-2的产生
Clin Immunol Immunopathol. 1986 Aug;40(2):375-9. doi: 10.1016/0090-1229(86)90043-7.
2
Detection of interleukin 2 in the urine of patients with superficial bladder tumors after treatment with intravesical BCG.膀胱内灌注卡介苗治疗后浅表性膀胱肿瘤患者尿液中白细胞介素2的检测
J Urol. 1986 Oct;136(4):970-4. doi: 10.1016/s0022-5347(17)45142-1.
3
Urinary interleukins in patients receiving intravesical Bacillus Calmette-Guerin therapy for superficial bladder cancer.接受卡介苗膀胱灌注治疗浅表性膀胱癌患者的尿液白细胞介素
Cancer. 1989 Oct 1;64(7):1447-54. doi: 10.1002/1097-0142(19891001)64:7<1447::aid-cncr2820640715>3.0.co;2-y.
4
Role of interleukin-8 in onset of the immune response in intravesical BCG therapy for superficial bladder cancer.白细胞介素-8在浅表性膀胱癌膀胱内卡介苗治疗免疫反应起始中的作用
Urol Res. 1997;25(1):31-4. doi: 10.1007/BF00941903.
5
Elevations of cytokines interleukin-1, interleukin-2 and tumor necrosis factor in the urine of patients after intravesical bacillus Calmette-Guerin immunotherapy.卡介苗膀胱内免疫治疗后患者尿液中细胞因子白细胞介素-1、白细胞介素-2和肿瘤坏死因子水平升高。
J Urol. 1990 Jul;144(1):59-64. doi: 10.1016/s0022-5347(17)39366-7.
6
Presence of interleukin-2 in urine of superficial bladder cancer patients after intravesical treatment with bacillus Calmette-Guérin.卡介苗膀胱内灌注治疗后浅表性膀胱癌患者尿液中白细胞介素-2的存在情况
Cancer Immunol Immunother. 1990;31(3):182-6. doi: 10.1007/BF01744734.
7
Detection of urinary interleukin-2, interleukin-2 receptor, and tumor necrosis factor levels in patients with superficial bladder tumors after intravesical BCG immunotherapy.浅表性膀胱肿瘤患者膀胱内卡介苗免疫治疗后尿白细胞介素-2、白细胞介素-2受体及肿瘤坏死因子水平的检测
Urology. 1994 Feb;43(2):187-90. doi: 10.1016/0090-4295(94)90042-6.
8
Urinary interleukin-2 monitoring during prolonged bacillus Calmette-Guerin treatment: can it predict the optimal number of instillations?卡介苗长期治疗期间尿白细胞介素-2监测：能否预测最佳灌注次数？
J Urol. 1999 Jan;161(1):67-71. doi: 10.1097/00005392-199901000-00024.
9
Urinary cytokines during intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer: processing, stability and prognostic value.卡介苗膀胱灌注治疗浅表性膀胱癌期间尿液细胞因子：处理、稳定性及预后价值
J Urol. 1996 Feb;155(2):477-82.
10
Intravesical bacille Calmette-Guérin induces the antiangiogenic chemokine interferon-inducible protein 10.膀胱内卡介苗可诱导抗血管生成趋化因子干扰素诱导蛋白10。
Urology. 1998 Aug;52(2):268-75; discussion 275-6.

引用本文的文献

1
Nonmuscle invasive bladder cancer: a primer on immunotherapy.非肌层浸润性膀胱癌：免疫治疗入门
Cancer Biol Med. 2016 Jun;13(2):194-205. doi: 10.20892/j.issn.2095-3941.2016.0020.
2
Evolving immunotherapy strategies in urothelial cancer.尿路上皮癌中不断发展的免疫治疗策略。
Am Soc Clin Oncol Educ Book. 2015:e284-90. doi: 10.14694/EdBook_AM.2015.35.e284.
3
Bladder Cancer Immunotherapy: BCG and Beyond.膀胱癌免疫疗法：卡介苗及其他。
Adv Urol. 2012;2012:181987. doi: 10.1155/2012/181987. Epub 2012 Jun 20.
4
Urinary interleukin-2 may predict clinical outcome of intravesical bacillus Calmette-Guérin immunotherapy for carcinoma in situ of the bladder.尿白细胞介素-2可能预测膀胱原位癌卡介苗膀胱内免疫治疗的临床结局。
Cancer Immunol Immunother. 2003 Aug;52(8):481-6. doi: 10.1007/s00262-003-0384-9. Epub 2003 Apr 18.
5
Enhancing the immunotherapeutic potential of mycobacteria by transfection with tumour necrosis factor-alpha.通过用肿瘤坏死因子-α转染增强分枝杆菌的免疫治疗潜力。
Immunology. 1999 Jan;96(1):114-21. doi: 10.1046/j.1365-2567.1999.00667.x.
6
The role of nitric oxide in bacillus Calmette-Guérin mediated anti-tumour effects in human bladder cancer.一氧化氮在卡介苗介导的人膀胱癌抗肿瘤效应中的作用
Br J Cancer. 1998 Sep;78(5):588-92. doi: 10.1038/bjc.1998.545.
7
Mechanisms of action of bacillus Calmette-Guérin in the treatment of superficial bladder cancer.卡介苗治疗浅表性膀胱癌的作用机制。
World J Urol. 1993;11(3):165-8. doi: 10.1007/BF00211413.
8
Increased urinary albumin indicating urothelial leakage following intravesical bacillus Calmette-Guérin therapy for superficial bladder cancer.
Urol Res. 1993;21(6):423-7. doi: 10.1007/BF00300079.
9
Changes in urinary cytokines and soluble intercellular adhesion molecule-1 (ICAM-1) in bladder cancer patients after bacillus Calmette-Guérin (BCG) immunotherapy.卡介苗（BCG）免疫治疗后膀胱癌患者尿细胞因子及可溶性细胞间黏附分子-1（ICAM-1）的变化
Clin Exp Immunol. 1995 Mar;99(3):369-75. doi: 10.1111/j.1365-2249.1995.tb05560.x.
10
Production of urinary tumour necrosis factors and soluble tumour necrosis factor receptors in bladder cancer patients after bacillus Calmette-Guérin immunotherapy.卡介苗免疫治疗后膀胱癌患者尿肿瘤坏死因子及可溶性肿瘤坏死因子受体的产生
Cancer Immunol Immunother. 1995 Feb;40(2):119-24. doi: 10.1007/BF01520294.